What are the side effects of Auvelity (dextromethorphan and bupropion)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Side Effects of Auvelity (Dextromethorphan and Bupropion)

The most common side effects of Auvelity include dizziness, nausea, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, hyperhidrosis, anxiety, constipation, decreased appetite, and insomnia. 1

Common Side Effects

Auvelity combines dextromethorphan and bupropion, with many of its side effects stemming from the bupropion component. The most frequently reported adverse effects include:

  • Neurological effects:

    • Dizziness
    • Headache
    • Somnolence (drowsiness)
    • Insomnia
  • Gastrointestinal effects:

    • Nausea
    • Dry mouth
    • Diarrhea
    • Constipation
    • Decreased appetite
  • Other common effects:

    • Sexual dysfunction
    • Hyperhidrosis (excessive sweating)
    • Anxiety

Serious Side Effects and Warnings

Seizure Risk

Seizures are a serious potential side effect of Auvelity, primarily due to the bupropion component. The risk increases at higher doses 1. Patients with a history of seizures, brain injuries, or conditions that lower seizure threshold should use this medication with extreme caution or avoid it altogether 2.

Psychiatric Effects

Like all antidepressants, Auvelity carries a boxed warning regarding increased risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults 1. The American College of Physicians recommends close monitoring for:

  • Suicidal ideation
  • Anxiety
  • Agitation
  • Mood changes 3

Cardiovascular Effects

Bupropion can cause increased blood pressure and heart rate, requiring regular monitoring, especially in patients with pre-existing cardiovascular conditions 3.

Contraindications

Auvelity should not be used in patients with:

  • Seizure disorders
  • Current use of MAO inhibitors
  • Uncontrolled hypertension
  • Conditions that lower seizure threshold
  • Anorexia or bulimia nervosa
  • Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs 4

Special Populations

Renal Impairment

For patients with moderate to severe renal impairment, the bupropion dose should be reduced by 50%, and it should be avoided in end-stage renal disease 4, 3.

Hepatic Impairment

In patients with moderate to severe hepatic impairment, bupropion dosing should not exceed one tablet daily 4, 3.

Elderly Patients

Lower starting doses should be considered for elderly patients due to increased risk of adverse effects 3.

Drug Interactions

Auvelity has significant drug interaction potential:

  • MAO inhibitors: Contraindicated due to risk of hypertensive crisis
  • Opioids: May reduce efficacy of opioid analgesics or precipitate withdrawal reactions due to naltrexone component 4
  • Alcohol: Limit or avoid alcohol during treatment 2
  • Medications that lower seizure threshold: Increased seizure risk 2

Clinical Efficacy Context

Despite these side effects, clinical trials have shown Auvelity to be effective for major depressive disorder with rapid onset of action. In long-term studies, remission rates approached 70%, while response rates were greater than 80% 5. This favorable efficacy profile may outweigh the side effect burden for many patients with depression.

Monitoring Recommendations

  • Regular monitoring of blood pressure and heart rate
  • Close observation for neuropsychiatric symptoms, especially during the first few months of treatment
  • Monitoring for seizure risk factors
  • Gradual dose titration to minimize side effects

Discontinuation

When discontinuing Auvelity, gradual tapering is recommended to minimize withdrawal symptoms, which may include neuropsychiatric symptoms, insomnia, headache, and mood changes 3.

References

Research

New Combination Drug for Depression.

The American journal of nursing, 2023

Guideline

Treatment of Comorbid Major Depressive Disorder and Attention Deficit Hyperactivity Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.